In vitro activity of tigecycline against strains isolated from diabetic foot ulcers

被引：18
作者：
Sotto, A.
Bouziges, N.
Jourdan, N.
Richard, J. -L.
Lavigne, J. -P.
机构：
[1] Univ Montpellier 1, UFR Med, Inst Natl Sante & Rech Med, ESPRI 26, F-30908 Nimes 02, France
[2] Univ Caremeau, Grp Hosp, Lab Bacteriol Virol Parasitol, F-30029 Nimes, France
[3] Univ Caremeau, Grp Hosp, Serv Malad Metab & Endocriniennes, F-30029 Nimes 09, France
[4] CHU Nimes, Serv Malad Nutr & Diabetol, F-30240 Le Grau Du Roi, France
来源：
PATHOLOGIE BIOLOGIE | 2007年 / 55卷 / 8-9期
关键词：
prevalence; MIC; epidemiology; infected diabetic foot ulcer;
D O I：
10.1016/j.patbio.2007.07.003
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Purpose of the study. - The aim of this study was to evaluate the in vitro activity of tigecycline and other comparator agents against bacterial strains isolated from diabetic foot infections (DFI). Patients and methods. - All diabetic patients hospitalized for a first episode of DFI(stage 2 to 4, according to the International Working Group of Diabetic Foot classification) were selected in Nimes University hospital between January 2005 and June 2006. MICs were determined using custom broth microdilution panels against bacterial strains isolated from foot samples. Results. - Three hundred fifteen strains were studied. Tigecycline was active against 83.7% of all the strains especially Gram-positive cocci (97.3%) in particular methicillin-resistant Staphylococcus aureus (96%), Enterobacteriaceae (88.5%) and anaerobes (100%). Exclusively Pseudomonas aeruginosa and Proteae were not covered by this antibiotic. Conclusions. - Tigecycline, a new broad spectrum antimicrobial agent, is qualified to belong to the therapeutic arsenal package of complicated skin and soft tissue infections in diabetic patients after microbial documentation. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：398 / 406
页数：9
相关论文
共 15 条
[1]   In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections [J].
Bradford, PA ;
Weaver-Sands, DT ;
Petersen, PJ .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S315-S332
[2]   TETRACYCLINES, MOLECULAR AND CLINICAL ASPECTS [J].
CHOPRA, I ;
HAWKEY, PM ;
HINTON, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 (03) :245-277
[3]  
Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE
[4]   Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 [J].
Dean, CR ;
Visalli, MA ;
Projan, SJ ;
Sum, PE ;
Bradford, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :972-978
[5]   Tigecycline: A glycylcycline antimicrobial agent [J].
Doan, Thien-Ly ;
Fung, Horatio B. ;
Mehta, Dhara ;
Riska, Paul F. .
CLINICAL THERAPEUTICS, 2006, 28 (08) :1079-1106
[6]  
*EUR COMM ANT SUSC, 2007, SUSC TEST TIG
[7]   MRSA and osteomyelitis of the foot in diabetes [J].
Game, F ;
Jeffcoate, W .
DIABETIC MEDICINE, 2004, 21 :16-19
[8]  
JARLIER V, 1988, REV INFECT DIS, V10, P867
[9]   Validation of the Infectious Diseases Society of America's diabetic foot infection classification system [J].
Lavery, Lawrence A. ;
Armstrong, David G. ;
Murdoch, Douglas P. ;
Peters, Edgar J. G. ;
Lipsky, Benjamin A. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (04) :562-565
[10]   Medical treatment of diabetic foot infections [J].
Lipsky, BA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 :S104-S114
12